Pennsylvania HR 220: A Resolution designating the week of May 4 through 10, 2025, as "Tardive Dyskinesia Awareness Week" in Pennsylvania.
Status: Referred to Human Services (as of 2025-05-01)
State: Pennsylvania · Session: 2025-2026 · Bill: HR 220
Sponsors: David Delloso, Arvind Venkat, Ben Waxman, Benjamin Sanchez, Carol Hill-Evans, Carol Kazeem, Ed Neilson, Justin Fleming, Michael Schlossberg, Nikki Rivera, Tarah Probst
Bill Text
PRINTER'S NO. 1564 THE GENERAL ASSEMBLY OF PENNSYLVANIA HOUSE RESOLUTION No. 220 Session of 2025 INTRODUCED BY DELLOSO, WAXMAN, SCHLOSSBERG, VENKAT, HILL-EVANS, KAZEEM, PROBST, SANCHEZ AND NEILSON, APRIL 30, 2025 REFERRED TO COMMITTEE ON HUMAN SERVICES, MAY 1, 2025 A RESOLUTION Designating the week of May 4 through 10, 2025, as "Tardive Dyskinesia Awareness Week" in Pennsylvania. WHEREAS, Many people with serious mental health conditions, such as bipolar disorder, major depressive disorder, schizophrenia and schizoaffective disorder, or with gastrointestinal disorders, including gastroparesis, upset stomach, nausea and vomiting, may be treated with medications that work as dopamine receptor blocking agents (DRBAs), including antipsychotics and antiemetics; and WHEREAS, While ongoing treatment with these medications can be necessary, prolonged use is associated with tardive dyskinesia (TD), an involuntary movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso, limbs, fingers or toes; and WHEREAS, Even mild symptoms of TD can impact people physically, socially and emotionally; and WHEREAS, It is estimated that TD affects approximately 800,000 people in the United States and approximately 60% of 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 people with TD have not been diagnosed, making it important to raise awareness about the symptoms; and WHEREAS, It is important that people taking DRBA medication be monitored for TD by a health care provider; and WHEREAS, The American Psychiatric Association recommends regular screenings for TD; and WHEREAS, Clinical research has led to approval of treatments for adults with TD by the United States Food and Drug Administration; and WHEREAS, Recognition and treatment of TD can make a positive impact in the lives of many people experiencing psychotic and mood disorders; and WHEREAS, The House of Representatives wants to raise awareness of TD among the public and medical community; therefore be it RESOLVED, That the House of Representatives designate the week of May 4 through 10, 2025, as "Tardive Dyskinesia Awareness Week" in Pennsylvania; and be it further RESOLVED, That the House of Representatives encourage people in this Commonwealth and across the United States to become better informed about and aware of tardive dyskinesia. 20250HR0220PN1564 - 2 - 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
View Pennsylvania HR 220 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.